The following information is missing from the Funding section: This work was supported by University of Wisconsin ICTR-Clinical and Type 1 Translational Research Pilot Program (UL1TR000427 to K.C.K.). This funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Citation: The PLOS ONE Staff (2014) Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation. PLoS ONE 9(10): e110098. https://doi.org/10.1371/journal.pone.0110098
Published: October 1, 2014
Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.